Tags

Type your tag names separated by a space and hit enter

Prevalence and risk factors for red blood cell alloimmunisation among sickle cell patients in Mwanza City, Tanzania.
Afr J Lab Med. 2020; 9(1):823.AJ

Abstract

Background

Erythrocyte alloimmunisation can lead to complications such as delayed haemolytic transfusion reaction.

Objective

This study investigated the prevalence of and risk factors for red blood cell alloimmunisation among multiply transfused sickle cell disease (SCD) patients in Mwanza City, Tanzania.

Methods

From May 2017 to July 2017, this descriptive, cross-sectional, hospital-based study enrolled 200 participants with SCD who had received at least two units of blood in the previous year. Blood count was performed using a Sysmex haematology analyser. Antibody screening was done by the tube method using a panel of three screening cells with known antigenicity.

Results

Of the 200 patients enrolled, 108 (54%) were female. The median age was 4.5 years (interquartile range [IQR] = 6), the median number of transfusions was 3 (IQR = 1), and the median pre-transfusion haemoglobin level was 6.6 g/dl (IQR = 2.7). Prevalence of alloimmunisation was 8.5% (17/200) with immunoglobulin G, and one patient developed cold immunoglobulin M antibodies. Blood groups reported were Rhesus C and E, Kell, Kidd and Duffy. There was no statistically significant association between the number of transfusions and the risk of alloimmunisation.

Conclusion

The rate of alloimmunisation in multiply transfused SCD patients was 8.5% and higher than other studies in East Africa. Thus, there is a need for extensive red blood cell screening and matching to minimize alloimmunisation and risk of delayed haemolytic transfusion reaction, particularly in SCD and chronically transfused patients.

Authors+Show Affiliations

Department of Pathology, Weill Bugando School of Medicine, Mwanza, United Republic of Tanzania. Bugando Medical Centre, Mwanza, United Republic of Tanzania.Central Pathology Laboratory, Bugando Medical Centre, Department of Hematology, Mwanza, United Republic of Tanzania.Department of Pathology, Weill Bugando School of Medicine, Mwanza, United Republic of Tanzania. Bugando Medical Centre, Mwanza, United Republic of Tanzania. Mwanza Region Health Center, Mwanza, United Republic of Tanzania.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33102164

Citation

Tebuka, Erius, et al. "Prevalence and Risk Factors for Red Blood Cell Alloimmunisation Among Sickle Cell Patients in Mwanza City, Tanzania." African Journal of Laboratory Medicine, vol. 9, no. 1, 2020, p. 823.
Tebuka E, Charles M, Bhuko JO. Prevalence and risk factors for red blood cell alloimmunisation among sickle cell patients in Mwanza City, Tanzania. Afr J Lab Med. 2020;9(1):823.
Tebuka, E., Charles, M., & Bhuko, J. O. (2020). Prevalence and risk factors for red blood cell alloimmunisation among sickle cell patients in Mwanza City, Tanzania. African Journal of Laboratory Medicine, 9(1), 823. https://doi.org/10.4102/ajlm.v9i1.823
Tebuka E, Charles M, Bhuko JO. Prevalence and Risk Factors for Red Blood Cell Alloimmunisation Among Sickle Cell Patients in Mwanza City, Tanzania. Afr J Lab Med. 2020;9(1):823. PubMed PMID: 33102164.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence and risk factors for red blood cell alloimmunisation among sickle cell patients in Mwanza City, Tanzania. AU - Tebuka,Erius, AU - Charles,Mwesige, AU - Bhuko,Jeffer O, Y1 - 2020/09/10/ PY - 2018/05/01/received PY - 2019/03/05/accepted PY - 2020/10/26/entrez PY - 2020/10/27/pubmed PY - 2020/10/27/medline KW - Bugando Medical Centre KW - Catholic University of Health and Allied Sciences KW - alloantibody KW - alloimmunisation KW - red blood cells KW - screening cells KW - sickle cell disease SP - 823 EP - 823 JF - African journal of laboratory medicine JO - Afr J Lab Med VL - 9 IS - 1 N2 - Background: Erythrocyte alloimmunisation can lead to complications such as delayed haemolytic transfusion reaction. Objective: This study investigated the prevalence of and risk factors for red blood cell alloimmunisation among multiply transfused sickle cell disease (SCD) patients in Mwanza City, Tanzania. Methods: From May 2017 to July 2017, this descriptive, cross-sectional, hospital-based study enrolled 200 participants with SCD who had received at least two units of blood in the previous year. Blood count was performed using a Sysmex haematology analyser. Antibody screening was done by the tube method using a panel of three screening cells with known antigenicity. Results: Of the 200 patients enrolled, 108 (54%) were female. The median age was 4.5 years (interquartile range [IQR] = 6), the median number of transfusions was 3 (IQR = 1), and the median pre-transfusion haemoglobin level was 6.6 g/dl (IQR = 2.7). Prevalence of alloimmunisation was 8.5% (17/200) with immunoglobulin G, and one patient developed cold immunoglobulin M antibodies. Blood groups reported were Rhesus C and E, Kell, Kidd and Duffy. There was no statistically significant association between the number of transfusions and the risk of alloimmunisation. Conclusion: The rate of alloimmunisation in multiply transfused SCD patients was 8.5% and higher than other studies in East Africa. Thus, there is a need for extensive red blood cell screening and matching to minimize alloimmunisation and risk of delayed haemolytic transfusion reaction, particularly in SCD and chronically transfused patients. SN - 2225-2002 UR - https://www.unboundmedicine.com/medline/citation/33102164/Prevalence_and_risk_factors_for_red_blood_cell_alloimmunisation_among_sickle_cell_patients_in_Mwanza_City,_Tanzania L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/33102164/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.